KR100563547B1 - A cosmetic composition containing extract of Lespedeza bicolor turczaninow var and/or Solanum nigrum L - Google Patents
A cosmetic composition containing extract of Lespedeza bicolor turczaninow var and/or Solanum nigrum L Download PDFInfo
- Publication number
- KR100563547B1 KR100563547B1 KR1020040035047A KR20040035047A KR100563547B1 KR 100563547 B1 KR100563547 B1 KR 100563547B1 KR 1020040035047 A KR1020040035047 A KR 1020040035047A KR 20040035047 A KR20040035047 A KR 20040035047A KR 100563547 B1 KR100563547 B1 KR 100563547B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- skin
- effect
- cosmetic composition
- whitening
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 94
- 239000002537 cosmetic Substances 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 240000000604 Lespedeza bicolor Species 0.000 title description 2
- 235000016677 Lespedeza bicolor Nutrition 0.000 title description 2
- 244000061457 Solanum nigrum Species 0.000 title description 2
- 235000002594 Solanum nigrum Nutrition 0.000 title description 2
- 230000002087 whitening effect Effects 0.000 claims abstract description 27
- 206010040880 Skin irritation Diseases 0.000 claims abstract description 15
- 239000006210 lotion Substances 0.000 claims abstract description 15
- 230000036556 skin irritation Effects 0.000 claims abstract description 15
- 231100000475 skin irritation Toxicity 0.000 claims abstract description 15
- 235000003840 Amygdalus nana Nutrition 0.000 claims abstract description 14
- 241000220299 Prunus Species 0.000 claims abstract description 14
- 235000011432 Prunus Nutrition 0.000 claims abstract description 14
- 235000014774 prunus Nutrition 0.000 claims abstract description 14
- 239000006071 cream Substances 0.000 claims abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000686 essence Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 44
- 210000003491 skin Anatomy 0.000 abstract description 30
- 230000008099 melanin synthesis Effects 0.000 abstract description 18
- 102000004190 Enzymes Human genes 0.000 abstract description 13
- 108090000790 Enzymes Proteins 0.000 abstract description 13
- -1 pack Substances 0.000 abstract description 12
- 239000000126 substance Substances 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000015572 biosynthetic process Effects 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 208000012641 Pigmentation disease Diseases 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 6
- 235000017848 Rubus fruticosus Nutrition 0.000 abstract description 5
- 244000078534 Vaccinium myrtillus Species 0.000 abstract description 5
- 235000021029 blackberry Nutrition 0.000 abstract description 5
- 230000030833 cell death Effects 0.000 abstract description 5
- 206010014970 Ephelides Diseases 0.000 abstract description 4
- 208000003351 Melanosis Diseases 0.000 abstract description 4
- 210000004927 skin cell Anatomy 0.000 abstract description 4
- 239000000758 substrate Substances 0.000 abstract description 4
- 241001415939 Corvus Species 0.000 abstract description 3
- 241000392950 Prunus japonica Species 0.000 abstract description 3
- 235000013999 Prunus japonica Nutrition 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 239000000419 plant extract Substances 0.000 abstract description 3
- XSKZXGDFSCCXQX-UHFFFAOYSA-N thiencarbazone-methyl Chemical compound COC(=O)C1=CSC(C)=C1S(=O)(=O)NC(=O)N1C(=O)N(C)C(OC)=N1 XSKZXGDFSCCXQX-UHFFFAOYSA-N 0.000 abstract description 3
- 240000000724 Berberis vulgaris Species 0.000 abstract description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 abstract description 2
- 235000005805 Prunus cerasus Nutrition 0.000 abstract description 2
- 240000002878 Prunus cerasus Species 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract description 2
- 239000000843 powder Substances 0.000 abstract description 2
- 230000000116 mitigating effect Effects 0.000 abstract 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 230000002401 inhibitory effect Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 21
- 239000000243 solution Substances 0.000 description 14
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 235000018185 Betula X alpestris Nutrition 0.000 description 8
- 235000018212 Betula X uliginosa Nutrition 0.000 description 8
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 229940100601 interleukin-6 Drugs 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 210000002752 melanocyte Anatomy 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000008213 purified water Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 244000184734 Pyrus japonica Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 230000003061 melanogenesis Effects 0.000 description 5
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- 102000004125 Interleukin-1alpha Human genes 0.000 description 4
- 108010082786 Interleukin-1alpha Proteins 0.000 description 4
- 229960000271 arbutin Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 229940069445 licorice extract Drugs 0.000 description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010003272 Hyaluronate lyase Proteins 0.000 description 3
- 102000001974 Hyaluronidases Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 240000002299 Symphytum officinale Species 0.000 description 3
- 235000005865 Symphytum officinale Nutrition 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 108060008724 Tyrosinase Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229960002773 hyaluronidase Drugs 0.000 description 3
- 210000002780 melanosome Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001164374 Calyx Species 0.000 description 2
- 240000001548 Camellia japonica Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102400000686 Endothelin-1 Human genes 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 235000003228 Lactuca sativa Nutrition 0.000 description 2
- 229920001007 Nylon 4 Polymers 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 2
- 240000001987 Pyrus communis Species 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 235000019714 Triticale Nutrition 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000018597 common camellia Nutrition 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000020717 hawthorn extract Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 2
- 229940055577 oleyl alcohol Drugs 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 241000228158 x Triticosecale Species 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001365101 Corica Species 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 241000510678 Falcaria vulgaris Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 235000015742 Nephelium litchi Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 235000010674 Prunella vulgaris Nutrition 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229920002055 compound 48/80 Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000011539 homogenization buffer Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003101 melanogenic effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003578 releasing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- WUUHFRRPHJEEKV-UHFFFAOYSA-N tripotassium borate Chemical compound [K+].[K+].[K+].[O-]B([O-])[O-] WUUHFRRPHJEEKV-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K93/00—Floats for angling, with or without signalling devices
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K95/00—Sinkers for angling
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Environmental Sciences (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 식물 추출물을 주요 활성성분으로 함유하는 화장료 조성물에 관한 것으로서, 본 발명의 화장료 조성물은 싸리나무 추출물 또는 까마중 추출물로부터 선택된 1종 이상을 주요 활성성분으로 함유함으로써 우수한 미백효과와 항염증 피부자극 완화효과를 제공한다.The present invention relates to a cosmetic composition containing a plant extract as a main active ingredient, the cosmetic composition of the present invention by containing at least one selected from the extract of Prunus quinquefolia or extract from the crow as the main active ingredient excellent whitening effect and anti-inflammatory skin irritation It provides a mitigating effect.
본 발명에 따른 싸리나무 추출물 또는 까마중 추출물은 기미, 주근깨 및 피부 색소 침착의 원인이 되는 물질인 멜라닌 합성에 관련된 신호전달물질의 합성을 억제함으로써 멜라닌 합성을 억제하여 미백효과를 나타낼 뿐만 아니라, 화학물질을 포함하는 화장품 기재에 의해 야기되는 피부세포 사멸을 억제하고, 염증 유발관련 효소 활성억제를 통한 피부자극 완화 및 면역증강작용 효과를 제공한다.The extract of Prunus japonica or Corvus alba according to the present invention inhibits the synthesis of a signaling substance related to melanin synthesis, which is a substance causing blemishes, freckles and skin pigmentation, thereby suppressing melanin synthesis and exhibiting a whitening effect. It inhibits the skin cell death caused by the cosmetic substrate, including the skin irritation and immune enhancing effect through the inhibition of inflammation-related enzyme activity.
따라서, 이러한 싸리나무 및 까마중 추출물을 함유함으로써 탁월한 피부 미백효과, 항염증, 피부 자극 완화효과를 가지는 화장수, 크림, 유액, 팩, 파우더 등의 화장료 조성물을 제조할 수 있다.Therefore, it is possible to prepare a cosmetic composition such as a lotion, cream, milky lotion, pack, powder and the like having excellent skin whitening effect, anti-inflammatory, skin irritation effect by containing the extracts of the barberry and horse.
싸리나무 추출물, 까마중 추출물, 미백, 피부자극 완화.Prunus vulgaris extract, black berry extract, whitening, skin irritation relief.
Description
본 발명은 식물 추출물을 주요 활성성분으로 함유하는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing the plant extract as the main active ingredient.
인간의 피부는 자외선, 환경오염으로 인한 오존 또는 대기 중에 존재하는 기타 유해한 물질에 반응하여 약하거나 심각한 자극을 받는다. 특히 자극에 의해 방출되는 산소 라디칼 및 비특이적 단백질 분해효소에 의해 피부는 손상되기 쉽다.Human skin is weak or severely irritated in response to ultraviolet light, ozone from environmental pollution or other harmful substances present in the atmosphere. In particular, the skin is susceptible to damage by oxygen radicals and nonspecific proteases released by stimulation.
피부색을 결정하는 인자로는 기본적으로 인종과 지역, 성별, 나이에 따른 차이를 배제하면 기미, 주근깨와 자외선 노출로 인한 태닝과 같은 부분 또는 전체적인 색소침착, 그 외에 여드름 및 흉터, 각질의 분포 상태와 혈액 순환, 스트레스, 건강상태 등이 있다. 이상의 인자들 가운데에서도 가장 중요한 인자는 색소침착이다.The factors that determine the color of the skin are basically the partial or total pigmentation such as tanning caused by blemishes, freckles and UV exposure, excluding the differences according to race, region, sex and age, and the distribution of acne, scars and keratin. Blood circulation, stress, and health. Among the above factors, the most important factor is pigmentation.
그러나 과도한 색소침착은 피부미용 관점에서 심각한 정신적 부담을 주어 정상적인 사회활동에 지장을 주기도 하고, 예로부터 동양권의 여성들은 하얗고 고운 피부를 선호해 왔으며 이를 미의 기준으로 삼아왔던 바 이러한 색소침착의 원인을 규명하여 이를 방지하고자 하는 연구가 계속되어 오고 있다.However, excessive pigmentation is a serious mental burden from the perspective of skin beauty, which impedes normal social activities. Since ancient times, Asian women have preferred white and fair skin, and this has been the standard of beauty. Research to identify and prevent this has been continued.
피부색에 영향을 주는 색소로는 멜라닌, 멜라조이드, 카로틴, 헤모글로빈 등이 있는데 이중 가장 중요한 것은 멜라닌으로, 멜라닌의 생합성에 영향을 미치는 가장 큰 요인은 자외선과 체내 호르몬 분비를 들 수 있다. 멜라닌은 자외선을 흡수 또는 산란시켜 자외선으로부터 피부가 손상되는 것을 방지하는데 큰 역할을 하는데, 특별한 최대흡수파장이 없으며 전 영역의 빛을 흡수한다. 또한 활성산소종을 제거하는 기능이 탁월하나, 때로는 멜라닌 자체가 활성산소를 발생시키기도 하며, 멜라닌 구조내의 카테콜이나 퀴논에 의하여 다른 물질을 환원시키거나 산화시키고, 멜라닌 자체가 자유라디칼의 성질을 나타내기도 한다.The pigments that affect skin color include melanin, melazoids, carotene, and hemoglobin, the most important of which is melanin, and the biggest factor affecting melanin biosynthesis is ultraviolet and hormone secretion. Melanin plays an important role in absorbing or scattering ultraviolet rays to prevent damage to the skin from ultraviolet rays. There is no special maximum absorption wavelength and it absorbs light in all areas. In addition, it is excellent in removing the active oxygen species, but sometimes melanin itself generates free radicals, and other substances are reduced or oxidized by catechol or quinone in the melanin structure, and melanin itself shows the properties of free radicals. Pray.
멜라닌의 생합성은 아미노산의 일종인 티로신이 멜라노사이트의 멜라노좀에서 티로시나제에 의해 산화되어 디하이드록시 페닐알라닌 (dihydroxy phenylalanine)으로 전환되는 것을 시작으로 계속되는 일련의 산화과정을 거쳐 갈색(pheomelanin), 흑색 (eumelanin)의 중합체로 형성된다. 이러한 생합성 과정은 멜라노좀이라는 특수한 형태의 갈색 세포내 소기관에서 진행되며 멜라닌 과립을 포함한 멜라노좀은 핵 주변 부위에서 수지상 돌기 끝부분으로 이동, 케라티노사이트의 식세포작용에 의해 세포질 내로 이동하고 이들은 케라티노사이트의 핵 주변에 축적된다.The biosynthesis of melanin is a series of oxidation processes, starting with the conversion of tyrosine, an amino acid, from the melanocytes of melanocytes to tyrocinase and dihydroxy phenylalanine, followed by brown (pheomelanin) and black (eumelanin). It is formed of a polymer of). This biosynthesis process is carried out in a special type of brown intracellular organelles called melanosomes. Melanosomes, including melanin granules, move from the periphery of the nucleus to the dendritic end, and then into the cytoplasm by the phagocytosis of keratinocytes. Accumulate around the nucleus of the site.
멜라닌의 합성과 멜라노좀의 수, 주위의 케라티노사이트로의 이동은 부분적으로 호르몬과 자외선 등에 영향을 받고 일차적으로는 유전적인 영향을 크게 받는 다. 그 밖에 티로시나제의 발현 및 멜라닌의 합성, 전송에 관여하는 세포내 조절인자인 싸이토카인 (cytokine), 구리, 아연, 철 등의 금속 이온 및 인터페론, 프로스타글란딘, 히스타민 등이 관여하는 것으로 알려져 있다 (박수남 : 대한화장품학회지, 25: 77-127, 1999).The synthesis of melanin, the number of melanosomes, and the movement to surrounding keratinocytes are partially affected by hormones and ultraviolet rays, and primarily by genetic effects. In addition, cytokines, such as cytokines, copper, zinc, and iron, which are involved in the expression of tyrosinase, the synthesis and transfer of melanin, and metal ions such as interferon, prostaglandin, and histamine are known to be involved. Society of Cosmetic Scientists, 25: 77-127, 1999).
싸이토카인은 세포들간의 신호를 보내는 생물학적 작용에 관여하는 분자로 그 범주는 매우 다양하다. 대부분은 단백질이거나 펩타이드이며 당이 부착되기도하며 대부분 분자량이 작은 단백질 (8~25 kDa)이며 단일 사슬로 이루어져 있다. 싸이토카인은 세포 성장, 세포 활성, 염증, 면역성, 조직 회복, 섬유증 (섬유 형성) 등의 형태 발생과 같은 모든 중요한 생물학적 작용을 조절한다. 싸이토카인의 예로는 인터루킨, 인터페론, 성장 인자 등 여러 가지를 들 수 있다.Cytokines are molecules involved in biological actions that send signals between cells, and their categories vary widely. Most are proteins or peptides, and sugars are attached. Most are small molecular weight proteins (8-25 kDa), consisting of a single chain. Cytokines regulate all important biological actions such as morphogenesis, cell growth, cell activity, inflammation, immunity, tissue repair, fibrosis (fiber formation), and the like. Examples of cytokines include various interleukins, interferons, growth factors, and the like.
이모카와(Imokawa) 등의 연구에 의하면 사람의 케라티노사이트에 UVB를 조사하면 인터루킨-1a (interleukin-1a, IL-1a)와 인터루킨-6 (interleukin-6, IL-6)의 현저한 생성과 관련 유전자의 과발현을 관찰할 수 있는 것으로 알려져 있다. 또한 IL-1a와 IL-6은 다시 케라티노싸이트의 엔도테린-1(endothelin-1, ET-1)의 발현을 유도하는데 이는 인접한 멜라노싸이트에 작용하여 멜라닌의 생합성에 중요한 역할을 한다는 사실이 알려져 있다 (G Imokawa, 외 : J. Biol. Chem., 267: 24675-24680, 1992, G Imokawa, 외: Pigment Cell Res., 10: 218-228, 1997). 따라서 IL-1a와 IL-6와 같은 싸이토카인의 발현을 억제함으로써 보다 근본적인 색소침착의 원인을 제거하여 미백효과를 기대할 수 있다.According to Imokawa et al., UVB irradiation in human keratinocytes is associated with significant production of interleukin-1a (IL-1a) and interleukin-6 (IL-6). It is known that overexpression of genes can be observed. In addition, IL-1a and IL-6 induce the expression of endothelin-1 (ET-1) in keratinocytes, which are known to act on adjacent melanocytes and play an important role in melanin biosynthesis. (G Imokawa, et al . : J. Biol. Chem. , 267: 24675-24680, 1992, G Imokawa, et al .: Pigment Cell Res. , 10: 218-228, 1997). Therefore, by suppressing the expression of cytokines such as IL-1a and IL-6, the whitening effect can be expected by eliminating the cause of more fundamental pigmentation.
이미 아스코르빈산(일본특개평 4-9320), 하이드로퀴논(일본특개평 6- 192062), 코직산(일본특개소 56-7710), 알부틴(일본특개평 4-93150) 및 일부의 추출물 등이 티로시나제 저해 활성을 가지고 있어 미백 화장료로 이용되고 있으나 화장품 제형 중에서의 안정성이 나빠 분해되어 착색되거나, 이취의 발생, 생체 레벨에서의 효능, 효과의 불분명 및 안전성 문제 등으로 그 사용이 제한되고 있는 실정이다.Ascorbic acid (JP-A 4-9320), hydroquinone (JP-A 6-192062), kojic acid (JP-A-56-7710), arbutin (JP-A 4-93150), and some extracts are already tyrosinase. It is used as a whitening cosmetic because it has an inhibitory activity, but its stability in cosmetic formulations is poorly degraded and colored, or its use is limited due to the occurrence of off-flavor, efficacy at the biological level, unclear effect and safety problems.
또한 최근 소비자들은 점차 특수한 조성에 따라 고품질의 기능적 특성을 가짐과 동시에 피부보호, 자극억제, 염증억제, 일광차단 등의 최소한의 부작용을 갖는 화장품의 사용을 요구하고 있고, 종래의 화학물질을 함유한 화장품은 미백효과 이외에 피부 자극 경감이라는 다기능적 측면을 충족시킬 수 없다는 문제점이 있었다.In addition, consumers are increasingly demanding the use of cosmetics with a minimum of side effects such as skin protection, irritation suppression, inflammation suppression, sun protection, etc., while having high quality functional properties according to a special composition. In addition to the whitening effect, cosmetics can not satisfy the multifunctional aspect of skin irritation.
본 발명은 이상과 같은 문제점을 해결하기 위하여 안출된 것으로, 본 발명의 목적은 여러 천연물들 중 쌍떡잎식물 장미목 콩과의 낙엽관목 식물인 싸리나무 추출물 또는 가지과의 일년초 까마중 추출물부터 선택된 1종 이상의 천연물로부터 제조된 추출물을 선택하여, 화장품 원료로서의 효능을 확인하고 그 사용방법을 개발함으로써, 다양한 화장품의 원료의 선택범위를 높이고, 또 이 원료를 사용하여 좀더 자극이 없으면서도 소정의 기능성 효과를 나타내는 화장품을 제조할 수 있는 방법을 제공하는 것이다.The present invention has been made in order to solve the above problems, an object of the present invention is selected from one or more natural products selected from the extract of Prunus bark, or Dec. By selecting the extracted extract, confirming its efficacy as a cosmetic raw material and developing a method of using the same, increasing the selection range of various cosmetic raw materials, and using this raw material to produce cosmetics having a predetermined functional effect without further stimulation. It is to provide a method that can be produced.
즉 본 발명의 목적은 기미, 주근깨 및 피부 색소 침착의 원인이 되는 물질인 멜라닌 합성을 억제하여 미백효과를 나타낼 뿐만 아니라, 화장품 기재에 의해 야기 되는 피부 자극을 경감시키는 피부세포 사멸 억제 효과, 염증 유발관련 효소 활성억제 효과 등의 피부자극 완화효과와 면역증강작용 효과를 나타내는 천연 추출물을 제공하는 것이다.That is, an object of the present invention is to inhibit melanin synthesis, which is a substance causing blemishes, freckles, and skin pigmentation, to have a whitening effect, and to inhibit skin cell death, to reduce skin irritation caused by cosmetic substrates, and to induce inflammation. It is to provide a natural extract showing a skin irritation-releasing effect and immune enhancing effect such as related enzyme activity inhibitory effect.
본 발명의 또 다른 목적은 싸리나무 및 까마중 추출물을 함유함으로써 피부 미백 효과, 항염증, 피부 자극 완화효과 등 우수한 효과를 나타내는 화장수, 크림, 유액, 팩, 파우더 등의 화장료 조성물을 제공하는 것이다.Still another object of the present invention is to provide a cosmetic composition such as a lotion, cream, milky lotion, pack, powder, etc., which has excellent effects such as skin whitening effect, anti-inflammatory, and skin irritation effect by containing extracts of Prunus chinensis and Crow.
이와 같은 목적을 달성하기 위한 본 발명은 싸리나무 추출물, 까마중 추출물 및 이들의 혼합물로 이루어지는 군에서 선택된 성분을 주요 활성성분으로 함유하는 화장료 조성물을 제공한다.The present invention for achieving the above object provides a cosmetic composition containing the main ingredient as an ingredient selected from the group consisting of Prunus chinensis extract, black rind extract, and mixtures thereof.
싸리나무는 쌍떡잎식물 장미목 콩과의 낙엽관목 식물로서 학명은 Lespedeza bicolor turczaninow var 이다. 산과 들에 흔히 자라며 턱잎은 가늘고 길며 짙은 갈색이고 길이 약 5mm이다. 작은잎은 달걀 모양이거나 달걀을 거꾸로 세워놓은 모양이다. 겉면은 짙은 녹색이며 뒷면에 눈털이 나고 가장자리가 밋밋하다. 꽃은 7∼8월에 붉은 자줏빛으로 피고 잎겨드랑이에 총상꽃차례로 달린다. 꽃받침은 얕게 4개로 갈라지고 뒤쪽의 1개는 다시 2개로 갈라지며 끝이 뾰족하다. 한방에서는 무좀, 습진, 마른버짐 등 갖가지 피부병 등에 사용하였다.Barberry is a deciduous shrub of the dicotyledonous plant Rosaceae, whose name is Lespedeza bicolor turczaninow var. Commonly growing in mountains and fields. Chin leaves are thin and long, dark brown, about 5mm long. Small leaves are egg-shaped or upside down. The outer side is dark green with snowy hair on the back and flat edges. Flowers bloom reddish purple in July-August. The calyx is shallowly divided into 4, the rear one is divided into 2 again, and the end is pointed. In oriental medicine, it was used for various skin diseases such as athlete's foot, eczema and dry ringworm.
까마중은 가지과의 일년초로서 학명은 Solanum nigrum L 이다. 저지대의 길가나 밭 주의에 자라며 높이 20~90cm이고 가지가 옆으로 많이 퍼지며 원줄기에 능선이 약간 나타난다. 잎은 호생하고 란형이며 예저 또는 둔두이고 원저 또는 넓은 예저이다. 긴 엽병의 윗부분까지 흐르고 길이 6~10cm, 폭 4~6cm로서 거치가 없거나 피상거치가 있다. 꽃은 5~7월에 피며 지름 6~7mm로서 백색이고, 화서는 잎보다 위에서 나오며 길이 1~3cm의 화경이 갈라지고 길이 3~8mm의 화경에 길이 7~12mm의 소화경이 있는 꽃이 산형으로 달린다. 꽃받침과 화관은 5개로 갈라지고 옆으로 퍼지며, 1개의 암술과 5개의 수술이 있다. 삭과는 둥글고 지름 6~7mm이며 흑색으로 익는다. 한방에서는 부인병, 치질, 악창, 만성 기관지염 등에 사용하였다.Camellia is the annual year of the branch family, the scientific name is Solanum nigrum L. It grows on the roadside or in the lowland of the lowlands. It is 20 ~ 90cm high, and branches are spread a lot, and some ridges appear on the main stem. Leaves are regenerated, egg-shaped, bottom or blunt, original or broad bottomed. It flows to the upper part of the long leaf, 6-10cm long, 4-6cm wide, with no cradle or superficial. Flowers bloom in May-July, 6-7mm in diameter, white, inflorescences come out from the leaves, and flowers of 1 ~ 3cm in length are split, flowers with 3 ~ 8mm in length, and 7-12mm in length are in the shape of mountains. Run Calyx and corolla split into 5 and spread laterally, with 1 pistil and 5 stamens. Capsules are round, 6-7mm in diameter, ripen in black. In oriental medicine, it was used for gynecological diseases, hemorrhoids, severe wounds, and chronic bronchitis.
상기와 같은 천연식물은 이전에는 미백효과가 있다고 알려져 있지 아니하였고 나아가 상기 천연식물의 추출물을 미백효과를 위해 응용한 예도 없었으며, 비로소 본 발명을 통하여 피부 미백, 항염증 및 피부 자극 완화 효과를 나타낸다는 것이 밝혀지게 된 것이다.Such natural plants have not previously been known to have a whitening effect, and furthermore, there was no example of applying the extract of the natural plant for the whitening effect, and it shows the skin whitening, anti-inflammatory and skin irritation effect through the present invention. Will be revealed.
본 발명에 사용된 싸리나무 추출물 또는 까마중 추출물은 싸리나무 또는 까마중으로부터 침출, 전출하여 얻은 침출액, 또는 그 침출액을 다시 일부 또는 전부 농축하여 얻은 농축물, 또는 다시 그 농축물을 건조시켜 제조한 추출 엑기스 및 추출액 중에 함유되고 있는 주효과를 발휘하는 화학물질 그 자체를 포함한다.The extract of Prunus chinensis or Corvus chinensis used in the present invention is a leachate obtained by leaching or transferring lychee from Apricot or Corica, or a concentrate obtained by partially or totally concentrating the leachate, or an extract extracted by drying the concentrate again. And the chemical substance itself having the main effect contained in the extract.
또한, 본 발명에 따른 싸리나무 추출물 또는 까마중 추출물 또는 이들의 혼합물의 함량은 화장료 조성물 전체에 대해서 동결건조중량 기준 0.001 내지 30.0 중량%인 것이 바람직하다. 상기 추출물의 함량이 0.001중량% 미만인 경우에는 피부개선 효과가 거의 없으며, 30.0중량% 이상인 경우에는 함유량 증가에 대한 효과 증대 정도가 미미하여 경제적이지 못하기 때문이다.In addition, it is preferable that the content of Prunus chinensis extract or the extract of Camellia according to the present invention or a mixture thereof is 0.001 to 30.0 wt% based on the total lyophilized weight of the cosmetic composition. When the content of the extract is less than 0.001% by weight, there is almost no skin improvement effect, and when the content of the extract is more than 30.0% by weight, it is not economical because the degree of increase of the effect on the content is insignificant.
또한 본 발명에 따른 화장료 조성물은 상기의 추출물 외에 본 발명이 목적으 로 하는 주효과를 손상시키지 않는 범위내에서 바람직하게는 주효과에 상승효과를 줄 수 있는 다른 성분 등을 함유하는 것도 무방하다.In addition, the cosmetic composition according to the present invention may contain, in addition to the above-mentioned extract, other ingredients that can give a synergistic effect to the main effect, preferably within the range of not impairing the main effect of the present invention.
상기 싸리나무 추출물 또는 까마중 추출물 또는 이들의 혼합물은 조성물 전체에 대하여 동결건조중량기준 0.001 내지 30.0 중량% 로 조성물 내에 존재할 수 있다. 만약 상기 식물추출물이 추출물을 함유하는 용액의 형태로 존재한다면 당업자는 상기 농도 범위 내에서 본 발명에 따른 조성물 내에 이 용액의 양을 조절할 수 있을 것이다.The birch extract or the extract in the yam or a mixture thereof may be present in the composition at 0.001 to 30.0% by weight based on the total lyophilized weight. If the plant extract is present in the form of a solution containing the extract, those skilled in the art will be able to adjust the amount of this solution in the composition according to the invention within the concentration range.
본 발명인 화장료 조성물은 추출용매로서 정제수, 메탄올, 에탄올, 글리세린, 에틸아세테이트, 부틸렌글리콜, 프로필렌글리콜, 디클로로메탄,헥산 및 그의 혼합물로부터 선택된 것을 사용한다.The cosmetic composition of the present invention uses a solvent selected from purified water, methanol, ethanol, glycerin, ethyl acetate, butylene glycol, propylene glycol, dichloromethane, hexane and mixtures thereof.
또한 본 발명의 주제는 피부 미백제, 항염증제, 피부 자극 완화제로 사용되는 화장료 조성물의 용도이다.Also subject of the present invention is the use of cosmetic compositions used as skin whitening agents, anti-inflammatory agents, skin irritants.
본 발명의 조성물은 수성, 수성-알콜성 또는 오일성 용액, 수중유 또는 유증수 또는 다중 에멀전, 수성 또는 오일성 겔, 액체, 페이스트성 또는 고체 무수 생성물, 소구체를 사용한 수성 상에서의 오일분산물의 형태일 수 있으며 보다 바람직하게는 이온성 및/또는 비이온성 형태의 지질 소포체의 형태일 수 있다.The compositions of the present invention may be in the form of an aqueous, aqueous-alcoholic or oily solution, oil-in-water or oily water or multiple emulsions, aqueous or oily gels, liquid, pasty or solid anhydrous products, oil dispersions in aqueous phase using globules. And more preferably in the form of lipid vesicles in ionic and / or nonionic form.
본 조성물은 다소 유체일수 있으며,백색 또는 유색크림, 연고, 밀크로션, 유액(serum), 에센스, 페이스트 또는 무스의 외관을 가질 수 있다. 이는 선택적으로 에어로졸 형태로 피부에 적용될 수도 있고, 고체 형태 예컨대, 스틱의 형태일 수도 있다. 이는 피부용 케어 제품 및/또는 메이크업 제품으로서 사용될 수도 있다.The composition may be somewhat fluid and may have the appearance of a white or colored cream, ointment, milk lotion, serum, essence, paste or mousse. It may optionally be applied to the skin in the form of an aerosol or may be in the form of a solid, such as a stick. It may be used as a skin care product and / or makeup product.
공지된 방식으로 본 발명에 따른 조성물은 또한 화장 분야에서 통상적인 보조제 예컨대 친수성 또는 친지성 겔화제, 친수성 또는 친지성 활성제, 보존제, 항산화제, 용매, 방향제, 충전제, 차단제, 안료, 흡취제 및 염료를 함유할 수 있다. 이들 다양한 보조제의 양은 당해 분야에서 통상적으로 사용되는 양이며, 예턴대 조성물 총중량에 대해 0.01 중량% 내지 20중량%이다. 그 성질에 따라 이러한 보조제는 지방상, 수성상, 지질 소포체 및/또는 나노입자에 도입될 수 있다. 어떠한 경우라도 보조제 및 그 비율은 본 발명에 따른 화장료 조성물의 바람직한 성질에 악영향을 미치지 않도록 선택될 것이다.In a known manner, the compositions according to the invention are also useful in conventional cosmetics such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, blockers, pigments, odorants and dyes. It may contain. The amounts of these various adjuvants are amounts commonly used in the art and are, for example, from 0.01% to 20% by weight relative to the total weight of the composition. Depending on their nature, such adjuvants may be incorporated into the fatty phase, aqueous phase, lipid vesicles and / or nanoparticles. In any case, the adjuvant and its proportions will be chosen so as not to adversely affect the desirable properties of the cosmetic composition according to the invention.
본 발명은 이제 하기의 실시예를 통하여 예증될 것이다. 단, 이들 실시예는 본 발명의 예시적인 기재일 뿐이며 본 발명의 범위가 이들 실시예에 국한되는 것은 아니다.The invention will now be illustrated by the following examples. However, these Examples are only illustrative description of the present invention and the scope of the present invention is not limited to these Examples.
실시예 1: 싸리나무 추출물 제조Example 1 Preparation of Hawthorn Extract
세절하여 음건한 싸리나무를 95%(V/V) 에탄올 수용액으로 5시간씩 3회 환류추출하고 냉침한 후, 와트만(Whatman) #5 여과지로 여과하였다. 여과된 추출물을 50℃ 이하에서 감압농축 및 동결건조하였다. 감압농축물 및 동결건조물이 0.001 내지 30.0 중량% 함유되게 정제수, 에탄올, 부틸렌글리콜, 프로필렌글리콜 중에서 선택된 1종 이상의 용매를 사용하여 분산/용해하여 싸리나무 추출물을 제조하였다.The dried bark was refluxed three times for 5 hours with 95% (V / V) ethanol aqueous solution, and the mixture was cooled and then filtered through Whatman # 5 filter paper. The filtered extract was concentrated under reduced pressure and lyophilized at 50 ° C or lower. The birch extract was prepared by dispersing / dissolving the depressurized concentrate and the lyophilised product using at least one solvent selected from purified water, ethanol, butylene glycol, and propylene glycol.
실시예 2: 까마중 추출물 제조Example 2: Preparation of extract in black yam
세절하여 음건한 까마중을 95%(V/V) 에탄올 수용액으로 5시간씩 3회 환류추출하고 냉침한 후, 와트만(Whatman) #5 여과지로 여과하였다. 여과된 추출물을 50℃ 이하에서 감압농축 및 동결건조하였다. 감압농축물 및 동결건조물이 0.001 내지 30.0중량% 함유되게 정제수, 에탄올, 부틸렌글리콜, 프로필렌글리콜 중에서 선택된 1종 이상의 용매를 사용하여 분산/용해하여 까마중 추출물을 제조하였다.The dried and dried dried black buckwheat was refluxed three times for 5 hours with 95% (V / V) ethanol aqueous solution, and then cooled and filtered through Whatman # 5 filter paper. The filtered extract was concentrated under reduced pressure and lyophilized at 50 ° C or lower. Extracts were prepared by dispersing / dissolving at least one solvent selected from purified water, ethanol, butylene glycol, and propylene glycol such that the vacuum concentrate and the lyophilisate were contained in an amount of 0.001 to 30.0% by weight.
실시예 3: B16F1 멜라닌형성세포를 이용한 멜라닌 생성 억제효과 측정 실험Example 3 Experiment for Determining Melanogenesis Inhibition Using B16F1 Melanogenic Cells
본 실시예는 실시예 1 내지 2에서 수득한 싸리나무 추출물 및 까마중 추출물의 미백효과를 확인하기 위해 B16F1 멜라닌형성세포에 대한 멜라닌 생성 억제 정도를 보고 미백효과를 평가한 것이다.This Example is to evaluate the whitening effect by looking at the degree of inhibition of melanin production on B16F1 melanocytes in order to confirm the whitening effect of the extract of Prunus chinensis and the extract from black yam obtained in Examples 1 to 2.
본 실시예에 사용된 B16F1 멜라닌형성세포는 마우스에서 유래한 세포균주이며, 멜라닌이라는 흑색색소를 분비하는 세포이다. 이 세포의 인공배양 중에 시료를 처리하여 멜라닌 흑색색소가 감소하는 정도를 비교 평가하였다. 본 실시예에 사용된 B16F1 멜라닌형성세포는 ATCC(American Type Culture Collection, 기탁번호 : 6323)로부터 분양받아 사용하였다.B16F1 melanocytes used in this example are cell strains derived from mice, and cells that secrete a black pigment called melanin. Samples were treated during the artificial culture of these cells to evaluate the degree of melanin black pigment reduction. B16F1 melanocytes used in this example were used by receiving from the ATCC (American Type Culture Collection, Accession No .: 6323).
B16F1 멜라닌형성세포의 멜라닌 생합성 억제효과 측정은 다음과 같이 행하였다.The melanin biosynthesis inhibitory effect of B16F1 melanogenesis cells was measured as follows.
B16F1 멜라닌형성세포를 6 웰 플레이트에 각 웰당 2 X 106 농도로 분주하고 세포를 부착시킨 후 독성을 유발하지 않는 농도로 시료를 처리하여 72시간 동안 배 양하였다. 72시간 배양 후 세포를 트립신-EDTA로 떼어 낸 후 세포수를 측정한 다음 원심분리하여 세포를 회수하였다. 세포내 멜라닌의 정량은 로탄(Lotan : Cancer Res., 40: 3345-3350, 1980)의 방법을 약간 변형하여 실시하였다. 셀 펠릿을 PBS로 1회 세척한 후 균질화 버퍼액(50 mM 소듐 포스페이트, pH 6.8, 1% Triton X-100, 2 mM PMSF) 1ml를 첨가하여 5분간 와류하여 세포를 파쇄하였다. 원심분리(3,000 rpm, 10분)하여 얻은 세포 여액에 1N NaOH(10% DMSO)를 첨가하여 추출된 멜라닌을 용해한 후 마이크로 플레이트 판독기로 405nm에서 멜라닌의 흡광도를 측정한 다음 멜라닌을 정량하여 시료의 멜라닌 생성저해율(%)을 측정하였다. B16F1 멜라닌형성세포의 멜라닌 생성저해율(%)은 수학식 1에 의하여 계산하였으며, IC50값은 멜라닌 생성을 50% 저해하는 물질의 농도이다.B16F1 melanocytes were divided into 6 well plates at a concentration of 2 X 10 6 per well, and the cells were attached and cultured for 72 hours by treating the samples at a concentration that does not cause toxicity. After 72 hours of incubation, the cells were detached with trypsin-EDTA, the cell number was measured, and the cells were recovered by centrifugation. Quantification of intracellular melanin was carried out with a slight modification of the method of Rotan: Cancer Res. , 40: 3345-3350, 1980. The cell pellet was washed once with PBS, and then 1 ml of homogenization buffer solution (50 mM sodium phosphate, pH 6.8, 1% Triton X-100, 2 mM PMSF) was added and vortexed for 5 minutes to disrupt cells. Melt the extracted melanin by adding 1N NaOH (10% DMSO) to the cell filtrate obtained by centrifugation (3,000 rpm, 10 minutes), and measure the absorbance of melanin at 405 nm with a microplate reader. Production inhibition rate (%) was measured. Melanin inhibition rate (%) of B16F1 melanogenesis cells was calculated according to Equation 1, IC 50 value is the concentration of the substance inhibiting 50% melanogenesis.
A : 시료를 첨가하지 않은 웰의 멜라닌 양A: Melanin amount in wells without sample
B : 시료를 첨가한 웰의 멜라닌 양B: Melanin amount in the wells to which the sample was added
B16F1 멜라닌형성세포의 멜라닌 생성 억제효과는 싸리나무 추출물의 IC50값은 0.1%로 나타났으며, 까마중 추출물의 IC50값은 0.15%로 나타나, 기존의 미백제인 하이드로퀴논, 알부틴, 유용성 감초 추출물, 상백피 추출물 등에 비해 유사하거나 우수한 효과를 나타내었다(표 1).Inhibition of melanin production of B16F1 melanogenesis cells showed an IC 50 value of 0.1%, and an IC 50 value of the extract of C. japonica was 0.15%. It showed a similar or superior effect as compared to the extract of the lettuce (Table 1).
실시예 4: 케라티노싸이트를 이용한 멜라닌 합성에 관련된 세포신호전달물질 저해 효과 측정Example 4 Measurement of Inhibitory Effect of Cell Signaling Agents Related to Melanin Synthesis Using Keratinocytes
본 실시예는 실시예 1 내지 2에서 수득한 싸리나무 추출물 및 까마중 추출물이 UVB에 의해 케라티노싸이트에서 분비가 촉진되어 멜라노싸이트의 멜라닌 형성을 촉진하는 물질인 인터루킨-1α, 인터루킨-6을 그 타겟으로 하는 것을 확인하기 위한 것이다. 인터루킨-1α, 인터루킨-6의 활성을 저해하면 이들의 멜라닌 합성 역시 저해된다. 이는 일상생활 속에 외부 자외선에 노출된 피부에서의 자외선에 의한 멜라닌 합성을 저해하는 것으로 미백제를 평가하기 위한 방법이다.This example targets the interleukin-1α and interleukin-6, which are substances which promote the secretion of keratinocytes by the UVB from the bark extracts and the extracts of the quince extracts obtained in Examples 1 to 2 to promote melanin formation of melanocytes. It is to confirm that it does. Inhibiting the activity of interleukin-1α and interleukin-6 also inhibits their melanin synthesis. This is a method for evaluating a whitening agent by inhibiting melanin synthesis by ultraviolet rays in skin exposed to external ultraviolet rays in daily life.
본 실시예는 사람의 피부로부터 분리된 케라티노싸이트 세포주로서 HaCaT (Boukamp P., et al., The Journal of Cell Biology, 106:761-771, 1988)을 사용하였으며, 싸리나무 추출물 및 까마중 추출물에 의한 세포의 신호 전달 물질인 싸이 토카인 저해 효과는 다음과 같이 측정하였다.In this example, HaCaT (Boukamp P., et al., The Journal of Cell Biology , 106: 761-771, 1988) was used as a keratinocyte cell line isolated from human skin. The cytokine inhibitory effect of the cell signal transduction agent was measured as follows.
HaCaT을 24웰 플레이트에 각 웰당 1X105농도로 분주하고 하루동안 세포를 부착시켰다. 다음날 세포배양배지를 제거하고 PBS로 세척한 후 6.8 mJ UVB를 세포에 조사하여 싸이토카인 분비를 촉진시키고, 싸리나무 추출물 및 까마중 추출물 10ppm을 세포에 처리하고 5시간 동안 배양하였다. 이때 사용한 세포배양배지에는 소의 혈청을 첨가하지 않았다. 5시간 후에 세포 배양 배지를 150㎕씩 96 웰 플레이트에 넣고 4℃에서 하루동안 코팅하였다. 배지를 제거하고 PBS-T(0.2% Tween20이 첨가된 PBS)로 3회 세척한 후 블록킹버퍼(3% Bovine Serum Albumin를 PBS-T에 녹인 것)를 두 시간 처리하였다. 버퍼를 제거하고 1차 항체인 항IL-1α, 항IL-6를 각각 블록킹버퍼로 희석하여 처리하였다. 90분 동안 37℃에서 반응시킨 후 3회 세척하고, 2차 항체인 항레빗-IgG를 처리한 후 90분 동안 37℃에서 반응시켰다. 5회 세척 후 기질 반응용액(833 mM 소듐 시트레이트, 385 mM 소듐 포스페이트, 0.1% H2O2, 0.0005% O-페닐렌디아민)을 웰당 150ul씩 넣고 37℃에서 40분 동안 반응시킨다. 2NH2SO4를 웰당 50㎕씩 넣어 반응을 중지하고, 490nm 에서 흡광도를 측정한 후 싸리나무 추출물 및 까마중 추출물의 인터루킨에 대한 저해 효과(%)를 수학식 2에 의해서 계산하였다.HaCaT was dispensed into 24 well plates at a concentration of 1 × 10 5 per well and cells were attached for one day. The next day, the cell culture medium was removed and washed with PBS to irradiate the cells with 6.8 mJ UVB to promote cytokine secretion, and 10 ppm of extracts of Prunus chinensis and Black Root were treated to the cells and incubated for 5 hours. At this time, bovine serum was not added to the cell culture medium used. After 5 hours, 150 μl of cell culture medium was placed in a 96 well plate and coated at 4 ° C. for one day. The medium was removed, washed three times with PBS-T (PBS with 0.2% Tween20), and then treated with blocking buffer (dissolved in 3% Bovine Serum Albumin in PBS-T) for two hours. The buffer was removed and the primary antibodies, anti-IL-1α and anti-IL-6, were diluted and treated with blocking buffers, respectively. After reacting at 37 ° C. for 90 minutes, the plate was washed three times, and then treated at 37 ° C. for 90 minutes after treatment with the anti-lebitt-IgG, which is a secondary antibody. After washing five times, the substrate reaction solution (833 mM sodium citrate, 385 mM sodium phosphate, 0.1% H 2 O 2 , 0.0005% O-phenylenediamine) is added to 150ul per well and reacted for 40 minutes at 37 ℃. 50 μl of 2NH 2 SO 4 was added per well to stop the reaction, and the absorbance was measured at 490 nm.
A : UVB를 처리한 후 시료를 처리하지 않은 웰의 흡광도A: absorbance of wells after treatment with UVB without treatment
B : UVB를 처리한 후 시료를 처리한 웰의 흡광도B: absorbance of wells treated with samples after UVB treatment
HaCaT 케라티노싸이트의 싸이토카인 합성 억제효과를 측정한 결과, 싸리나무 추출물 및 까마중 추출물의 IC50값은 인터루킨-1α에 대해 0.005-0.01%, 인터루킨-6 에 대해 0.001-0.008%로 나타나 기존에 알려진 미백제인 알부틴에 비해 우수한 효과를 나타내었다(표 2).As a result of measuring the inhibitory effect of cytokine synthesis of HaCaT keratinocytes, IC 50 values of P. japonica extract and C. japonica extract were 0.005-0.01% for interleukin-1α and 0.001-0.008% for interleukin-6. It showed a superior effect compared to phosphorus arbutin (Table 2).
이와 같은 결과로 볼 때, 본 발명의 싸리나무와 까마중 추출물의 경우에는 기존의 미백제가 단순히 티로시나제 효소의 활성만을 저해하는 것과는 달리 멜라닌 생합성에 관여하는 세포 신호전달물질의 합성을 저해하여 미백효과를 나타내는 것을 알 수 있다.As a result, in the case of the extract of Prunus chinensis and Corvus of the present invention, unlike the conventional whitening agent, which merely inhibits the activity of tyrosinase enzyme, the whitening effect is inhibited by inhibiting the synthesis of cell signaling material involved in melanin biosynthesis. It can be seen that.
실시예 5: 염증유발관련 효소 (hyaluronidase) 활성 억제효과 측정 실험Example 5 Experiment for Determining Inhibitory Effect of Inflammation-Related Enzyme (hyaluronidase) Activity
본 실시예는 실시예 1 내지 2에서 수득한 싸리나무 추출물 및 까마중 추출물 의 항염증 효과를 확인하기 위해 염증유발관련 효소인 히아루로니디아제의 효소 활성을 측정하여 판단한 것이다.This Example is determined by measuring the enzyme activity of hyaluroniadiaze, an inflammation-associated enzyme, hyaluroniadiasis, in order to confirm the anti-inflammatory effects of the extract of Prunus chinensis and the extract from Crow.
히아루로니디아제는 히아루론산을 가수분해하는 효소로 염증을 유발하는 기능을 가지고 있다. 본 실시예에서는 이 효소의 활성을 억제하여 항염증효과를 측정하는 방법(Kakegawa Y., Japanese J. of Inflammantion, 4:437-438, 1984)을 응용해 항염증효과를 판정하였다.Hyaluronidase is an enzyme that hydrolyzes hyaluronic acid and has a function of causing inflammation. In this example, the anti-inflammatory effect was determined by applying a method (Kakegawa Y., Japanese J. of Inflammantion , 4: 437-438, 1984) to inhibit the activity of this enzyme to measure the anti-inflammatory effect.
컴프리, 시소, 삼백초, 유용성 감초 추출물, 싸리나무 및 까마중 추출물을 시료로 사용하여 히아루로니디아제 활성 억제 효과를 조사하였다.The inhibitory effect of hyaluronidiase activity was investigated using comfrey, seesaw, triticale, oil-soluble licorice extract, Prunella vulgaris, and extracts from black yam as samples.
각 시료들의 히아루로니디아제에 대한 저해활성은 다음과 같이 행하였다.Inhibitory activity of hyaluronidiases of each sample was performed as follows.
시료 100㎕와 히아루로니디아제 용액(type Ⅳ-S, Sigma사, 400 U/ml) 50㎕를 넣고 37℃ 에서 20분간 반응시킨 후, 효소활성화용액(compound 48/80 CaCl2??2H2O, Sigma 사, 0.1 mg/ml)을 100㎕를 첨가하고 다시 37℃에서 20분간 반응시킨다. 히아루론산(hyaluronic acid) 용액(0.4 mg/ml)을 250㎕ 넣고 37℃에서 40분간 반응시키고, 0.4N NaOH 100㎕를 넣어 반응을 종결시킨다. 포타슘보레이트 용액을 100㎕를 첨가하여 95℃에서 3분간 반응시키고 냉각시킨 다음 ρ-디메틸아미노벤즈알데히드 용액을 3㎖ 넣고 다시 20분간 37℃에서 반응시켜 발색시킨다. 585nm에서 흡광도를 측정하여 히아루로니디아제에 대한 저해율을 측정하였다. 히아루로니디아제에 대한 저해율(%)은 수학식 3에 의하여 계산하였으며, IC50값은 히아루로니디아제 효소 활성을 50% 저해하는 물질의 농도이다.100 μl of sample and 50 μl of hyaluronidiase solution (type IV-S, Sigma, 400 U / ml) were added and reacted at 37 ° C. for 20 minutes, followed by enzyme activation solution (compound 48/80 CaCl 2 ?? 2H 2 O, Sigma). Inc., 0.1 mg / ml) was added to 100 µl and reacted again at 37 ° C. for 20 minutes. 250 μl of hyaluronic acid solution (0.4 mg / ml) was added and reacted at 37 ° C. for 40 minutes. 100 μl of 0.4N NaOH was added to terminate the reaction. 100 μl of potassium borate solution was added thereto, reacted at 95 ° C. for 3 minutes, cooled, and 3 ml of ρ-dimethylaminobenzaldehyde solution was added thereto. Absorbance was measured at 585 nm to determine the inhibition rate for hyaluronidiases. Inhibition rate (%) for hyaluronidiases was calculated by the equation (3), IC 50 value is the concentration of a substance that inhibits the hyaluronidiase enzyme activity by 50%.
A : 시료를 첨가하지 않은 웰의 효소활성A: Enzyme activity of wells without sample
B : 시료를 첨가한 웰의 효소 활성B: Enzyme Activity of Well Added Samples
히아루로니디이제 효소활성 억제효과를 시험한 결과 싸리나무 추출물 과 까마중 추출물의 IC50값은 0.08 내지 0.1%로 나타나 히아루로니디아제 저해효과가 뛰어나다고 알려진 기존의 항염증제인 유용성 감초 추출물, 컴프리 추출물, 삼백초 추출물, 시소 추출물 등에 비해 비슷하거나 우수한 효과를 나타내었다(표 3).As a result of testing the inhibitory effect of hyaluroniidase enzyme, IC 50 values of P. japonica extract and C. japonica extracts were 0.08 to 0.1%, which is a useful anti-inflammatory agent, a useful licorice extract and a comfrey extract, which are known to be excellent in inhibiting hyaluronidase. Compared to the three hundred seconds extract, seesaw extract and the like or showed an excellent effect (Table 3).
실시예 6: 세포 배양기술을 이용한 자극완화 효과 평가Example 6 Evaluation of Stimulation Relaxation Effect Using Cell Culture Technology
본 실시예는 실시예 1 내지 2에서 수득한 싸리나무 추출물 및 까마중 추출물의 자극완화 효과를 평가하기 위하여 세포 배양 기술을 이용하여 피부 자극을 유발 하는 물질인 소듐라우릴썰페이트(Sodium Lauryl Sulfate; SLS)에 의한 세포 사멸을 저해시키는 정도로 자극완화 효과를 평가한 것이다.This Example is a sodium lauryl sulfate (Sodium Lauryl Sulfate; SLS) that is a substance that causes skin irritation by using a cell culture technology in order to evaluate the stimulating relaxation effect of the extracts of Prunus chinensis and the extracts from the yam obtained in Examples 1 to 2 The effect of stimulating relaxation was evaluated to the extent of inhibiting cell death by).
SLS는 화장품 기재의 피부 자극 평가의 기준이 되는 물질로 세포막에 결합되어 세포대사 억제와 세포막을 파괴하여 피부자극을 유발하는 물질이다.SLS is a substance that is used as a criterion for evaluation of skin irritation based on cosmetics. It is bound to cell membranes to inhibit cell metabolism and destroys cell membranes to cause skin irritation.
본 실시예는 사람 섬유아세포에 SLS와 싸리나무, 까마중 추출물을 동시에 첨가하였을 때 SLS에 의한 세포 사멸을 감소시키는 효과를 평가한 것이다.This example evaluates the effect of reducing the cell death by SLS when SLS, fern, and horsetail extract were simultaneously added to human fibroblasts.
본 실시예에 사용된 Hs68 섬유아세포는 사람의 피부 진피세포로 ATCC (American Type Culture Collection, 기탁번호 1635)에서 분양받아 사용하였다.The Hs68 fibroblasts used in this example were used as a dermal dermal cell in humans, sold at ATCC (American Type Culture Collection, Accession No. 1635).
세포배양기술을 이용한 자극완화 평가 실험은 다음과 같이 행하였다.Stimulation relaxation evaluation experiment using the cell culture technology was carried out as follows.
사람 유래의 섬유아세포를 96웰 플레이트에 각 웰당 1X105 농도로 분주하고, 24시간 동안 배양한 후 0.01% SLS 단독, 0.01% SLS와 싸리나무 및 까마중 추출물을 각각 0.01%(w/w)를 동시에 처리하고 24시간 동안 추가배양하였다. 배양 후 MTT(Sigma사) 시약을 첨가하고 4시간 동안 배양한 후, 배양액을 제거하고 1N NaOH/이소프로판올용액을 첨가하여 20분간 교반한 후 마이크로플레이트 판독기로 565 nm에서 흡광도를 측정하여 싸리나무와 까마중 추출물이 SLS에 의한 세포사멸을 저해하는 효과를 측정하였다.Human-derived fibroblasts were dispensed in 96-well plates at a concentration of 1 × 10 5 per well and incubated for 24 hours, followed by 0.01% SLS alone, 0.01% SLS and 0.01% (w / w) extracts of Prunus japonica and black yam respectively. Treated and further incubated for 24 hours. After incubation, MTT (Sigma) reagent was added and incubated for 4 hours, the culture solution was removed, 1N NaOH / isopropanol solution was added and stirred for 20 minutes, and the absorbance was measured at 565 nm using a microplate reader. The effect of the extract on inhibiting apoptosis by SLS was measured.
실험결과 싸리나무 추출물과 까마중 추출물이 SLS에 의해서 유발되는 세포사멸을 억제시킴으로써 화장료 기재와 함께 처방하였을 때 화장료 기재로 일어날 수 있는 피부 자극을 감소시키는 자극완화 물질임이 밝혀졌다(표 4).As a result, it was found that the extract of Prunus japonica and the extract in the black yam are irritant substances that reduce skin irritation that can occur when the cosmetic base is prescribed with the cosmetic base by inhibiting apoptosis induced by SLS (Table 4).
실시예 7 내지 8 및 비교예 1Examples 7 to 8 and Comparative Example 1
본 실시예는 실시예 1, 2에서 수득한 싸리나무 추출물 및 까마중 추출물을 함유한 화장료를 제조하여 사람을 대상으로 피부 미백효과를 비교예 1과 비교실험을 행하여 평가하였다.The present Example was prepared by the cosmetics containing the extract of Prunus chinensis and the extract from the black horse obtained in Examples 1 and 2 to evaluate the skin whitening effect in Comparative Experiment with Comparative Example 1.
비교실험에 사용된 화장료는 크림형태이고, 그 조성은 표 5에 나타낸 바와 같다. 우선 표 5에 기록되어 있는 나)상을 가열하여 70℃에 보존한다. 이것에 가)상을 가하여 예비유화 후 호모믹서로 균일하게 유화하고 다음에 서서히 냉각하여 크림 (실시예 7, 8, 비교예 1)을 제조한다. 실험자 (20세-35세의 여성) 20명을 대상으로 얼굴 오른쪽 부위에는 실시예 7 내지 8에서 제조된 크림을, 얼굴 왼쪽 부위에는 비교예 1에서 제조된 크림을 각각 1일 2회씩 연속 2개월간 도포하였다. 시험 완료 후 얼굴 좌우 양편의 도포 부위 피부를 화상분석기 및 피부색의 변화를 크로마메타(Minolta CR300)를 이용하여 색의 밝기변화(ΔL)를 측정하고, 복수의 숙련자에 의한 객관적 육안 관찰과 피검자에 의한 주관적 육안관찰을 실시하여 하기 등급 분류에 따라 효과를 측정하였다. 그 결과를 하기 표 6에 나타내었다. 이때 미백효능 정도를 다음의 7등급으로 분류하여 평가하였다.The cosmetics used in the comparative experiments are in the form of a cream, the composition of which is shown in Table 5. First, the phase b) recorded in Table 5 is heated and stored at 70 ° C. To this, a) phase is added, and after pre-emulsification, it is emulsified uniformly with a homomixer and then cooled slowly to prepare a cream (Example 7, 8, Comparative Example 1). For 20 experimenters (20-35 year old female), the cream prepared in Examples 7 to 8 on the right side of the face and the cream prepared in Comparative Example 1 on the left side of the face for 2 consecutive days Applied. After completion of the test, the color of the applied areas on both sides of the face was measured using an image analyzer and the color of the skin using chromameter (Minolta CR300) to measure the change in brightness of the color (ΔL). Subjective visual observation was performed and the effect was measured according to the following classification. The results are shown in Table 6 below. At this time, the degree of whitening efficacy was classified into the following seven ratings.
미백효능 평가기준 :Whitening efficacy evaluation criteria:
-3: 매우 악화, -2: 악화, -1: 약간 악화,-3: very worse, -2: worse, -1: slightly worse,
0: 변화 없음, 1: 약간 개선, 2: 개선, 3: 매우 개선 0: no change, 1: slightly improved, 2: improved, 3: greatly improved
표 5에서 나타낸 바와 같이 싸리나무 추출물 및 까마중 추출물을 함유한 크림을 도포한 실험자의 안면 피부에서 미백효과가 우수함을 알 수 있다.As shown in Table 5, it can be seen that the whitening effect is excellent in the facial skin of the experimenter who applied the cream containing Prunus vulgaris and the extract of Crow.
주)단위: 중량%Note) Unit: Weight%
이하 그 외의 실시예를 나타내었다. 즉, 실시예 1, 2에서 수득한 싸리나무 추출물 및 까마중 추출물을 함유한 화장수, 유액 및 미용액을 실시예 9 내지 14에서 제조하였다.Other examples are shown below. That is, lotion, milky lotion and essence containing the extract of Prunus chinensis and the extract from black yam obtained in Examples 1 and 2 were prepared in Examples 9-14.
이들 싸리나무 추출물 및 까마중 추출물을 함유한 화장수, 유액 및 미용액은 탁월한 피부 미백효과 및 자외선에 의한 피부손상 억제 또는 자극완화 기능 등 피부개선에 우수한 효과를 나타내었다. 이들 싸리나무 추출물 및 까마중 추출물은 화장수, 젤, 수용성 리퀴드, 크림, 에센스, 수중유(O/W)형 및 유중수(W/O)형의 제형에 첨가하여 화장료를 제조할 수 있으며, 이는 당업자가 속한 기술분야에서 용이하게 적용할 수 있으며, 본 발명의 내용이 여기에 한정되지는 않는다.The lotion, milky lotion and essence containing these extracts of hawthorn extract and black berry showed excellent effects on skin improvement such as excellent skin whitening effect and skin damage suppression or irritation relief function by ultraviolet rays. These birch extracts and extracts of black yam can be added to the formulations of the lotion, gel, water-soluble liquid, cream, essence, oil-in-water (O / W) and water-in-oil (W / O) type, which is a person skilled in the art It can be easily applied in the technical field to which it belongs, but the content of the present invention is not limited thereto.
실시예 9: 실시예 1에서 수득한 싸리나무 추출물을 함유한 화장수의 제조Example 9: Preparation of a lotion containing a birch extract obtained in Example 1
95% 에탄올 8g에 폴리피로리돈 0.05g, 올레일알콜 0.1g, 폴리옥시에틸렌모노올레이트 0.2g, 향료 0.2g, 파라옥시안식향산메틸에스테르 0.1g, 소량의 산화방지제, 소량의 색소를 혼합 용해한다. 실시예 1에서 수득한 싸리나무 추출물 0.05g, 글리세린 5g을 정제수 85.33g에 용해한 것에 상기 혼합액을 첨가한 후 교반하여 피부개선효과가 있는 화장수를 얻었다.To 8 g of 95% ethanol, 0.05 g of polypyrrolidone, 0.1 g of oleyl alcohol, 0.2 g of polyoxyethylene monooleate, 0.2 g of fragrance, 0.1 g of paraoxybenzoic acid methyl ester, a small amount of antioxidant and a small amount of pigment are dissolved. . 0.05 g and 4 g of glycerol extract obtained in Example 1 were dissolved in 85.33 g of purified water, and then the mixed solution was added and stirred to obtain a lotion having a skin improvement effect.
실시예 10: 실시예 2에서 수득한 까마중 추출물을 함유한 화장수의 제조Example 10 Preparation of Lotion Containing the Extract of Black Root Obtained in Example 2
95% 에탄올 8g에 폴리피로리돈 0.05g, 올레일알콜 0.1g, 폴리옥시에틸렌모노올레이트 0.2g, 향료 0.2g, 파라옥시안식향산메틸에스테르 0.1g, 소량의 산화방지 제, 소량의 색소를 혼합용해 한다. 실시예 2에서 수득한 까마중 추출물 0.05g, 글리세린 5g을 정제수 85.33g에 용해한 것에 상기 혼합액을 첨가한 후 교반하여 피부개선효과가 있는 화장수를 얻었다.8 g of 95% ethanol, 0.05 g of polypyrrolidone, 0.1 g of oleyl alcohol, 0.2 g of polyoxyethylene monooleate, 0.2 g of fragrance, 0.1 g of paraoxybenzoic acid methyl ester, a small amount of antioxidant and a small amount of pigment do. 0.05 g of the extract obtained in Example 2, 5 g of glycerine was dissolved in 85.33 g of purified water, and then the mixed solution was added and stirred to obtain a lotion having a skin improvement effect.
실시예 11: 실시예 1에서 수득한 싸리나무 추출물을 함유한 유액의 제조Example 11 Preparation of Latex Containing Botanica Extract Obtained in Example 1
세틸알콜 1.2g, 스쿠알란 10g, 바세린 2g, 파라옥시안식향산에틸에스테르 0.2g, 글리세린모노에스테아레이드 1g, 폴리옥시에틸렌(20몰부가)모노올레이트 1g 및 향료 0.1g을 70℃에서 가열혼합용해하고, 실시예 1에서 수득한 싸리나무 추출물 0.5g, 디프로필렌글리콜 5g, 폴리에틸렌글리콜-1500 2g, 트리에탄올아민 0.2g, 정제수 76.2g을 75℃로 가열해서 용해시킨다. 양자를 혼합하여 유화시킨 후 냉각하여 수중유(O/W)형의 피부개선효과가 있는 유액을 얻었다.1.2 g of cetyl alcohol, 10 g of squalane, 2 g of petrolatum, 0.2 g of paraoxybenzoic acid ethyl ester, 1 g of glycerin monoesteralide, 1 g of polyoxyethylene (20 mole added) monooleate and 0.1 g of fragrance were mixed and dissolved at 70 ° C. , 0.5 g of the cedar extract obtained in Example 1, 5 g of dipropylene glycol, 2 g of polyethylene glycol-1500, 0.2 g of triethanolamine, and 76.2 g of purified water were dissolved by heating to 75 ° C. Both mixtures were emulsified and cooled to obtain an emulsion having an oil-in-water (O / W) type skin improvement effect.
실시예 12: 실시예 2에서 수득한 까마중 추출물을 함유한 유액의 제조Example 12 Preparation of an Milky Milk Containing an Extract of Black Root Obtained in Example 2
세틸알콜 1.2g, 스쿠알란 10g, 바세린 2g, 파라옥시안식향산에틸에스테르 0.2g, 글리세린모노에스테아레이드 1g, 폴리옥시에틸렌(20몰부가)모노올레이트 1g 및 향료 0.1g을 70℃에서 가열혼합용해하고, 실시예 2에서 수득한 까마중 추출물 0.5g, 디프로필렌글리콜 5g, 폴리에틸렌글리콜-1500 2g, 트리에탄올아민 0.2g, 정제수 76.2g을 75℃로 가열해서 용해시킨다. 양자를 혼합하여 유화시킨 후 냉각하여 수중유(O/W)형의 피부개선효과가 있는 유액을 얻었다.1.2 g of cetyl alcohol, 10 g of squalane, 2 g of petrolatum, 0.2 g of paraoxybenzoic acid ethyl ester, 1 g of glycerin monoesteralide, 1 g of polyoxyethylene (20 mole added) monooleate and 0.1 g of fragrance were mixed and dissolved at 70 ° C. , 0.5 g of the extract obtained from Example 2, 5 g of dipropylene glycol, 2 g of polyethylene glycol-1500, 0.2 g of triethanolamine, and 76.2 g of purified water were heated to 75 ° C. to dissolve it. Both mixtures were emulsified and cooled to obtain an emulsion having an oil-in-water (O / W) type skin improvement effect.
실시예 13: 실시예 1에서 수득한 싸리나무 추출물을 함유한 미용액의 제조Example 13: Preparation of Beauty Solution Containing Botanica Extract Obtained in Example 1
95% 에틸알콜 5g에 폴리옥시에틸렌솔비탄모노올레이트 1.2g, 키툴로오즈 0.3g, 히야론산나트륨 0.2g, 비타민 E-아세테이트 0.2g, 감초산 나트륨 0.2g, 파라옥시안식향산에틸에스테르 0.1g, 실시예 1에서 수득한 싸리나무 추출물 1g 및 적량의 색소를 혼합하여 피부개선 효과가 있는 미용액을 얻었다.5 g of 95% ethyl alcohol, 1.2 g of polyoxyethylene sorbitan monooleate, 0.3 g of kitulose, 0.2 g of sodium hyaluronate, 0.2 g of vitamin E-acetate, 0.2 g of sodium licorice, 0.1 g of paraoxybenzoic acid ethyl ester, 1 g of the birch extract obtained in Example 1 and an appropriate amount of pigments were mixed to obtain a essence having a skin improvement effect.
실시예 14: 실시예 2에서 수득한 까마중 추출물을 함유한 미용액의 제조Example 14 Preparation of a Cosmetic Solution Containing the Extract of Black Root Obtained in Example 2
95% 에틸알콜 5g에 폴리옥시에틸렌솔비탄모노올레이트 1.2g, 키툴로오즈 0.3g, 히야론산나트륨 0.2g, 비타민 E-아세테이트 0.2g, 감초산 나트륨 0.2g, 파라옥시안식향산에틸에스테르 0.1g, 실시예 2에서 수득한 까마중 추출물 1g 및 적량의 색소를 혼합하여 피부개선효과가 있는 미용액을 얻었다.5 g of 95% ethyl alcohol, 1.2 g of polyoxyethylene sorbitan monooleate, 0.3 g of kitulose, 0.2 g of sodium hyaluronate, 0.2 g of vitamin E-acetate, 0.2 g of sodium licorice, 0.1 g of paraoxybenzoic acid ethyl ester, In the extract obtained in Example 2, 1g of the extract and a suitable amount of pigments were mixed to obtain a cosmetic liquid having a skin improvement effect.
이상에서 설명된 바와 같이, 본 발명은 기미, 주근깨 및 피부 색소 침착의 원인이 되는 물질인 멜라닌 합성에 관련된 신호전달물질의 합성을 억제함으로써 멜라닌 합성을 억제하여 미백효과를 나타낼 뿐만 아니라, 화장품 기재에 의해 야기되는 피부 자극을 경감시키는 피부세포 사멸 억제 효과, 염증 유발관련 효소 활성억제 효과 등의 피부자극 완화효과와 면역증강작용 효과를 나타내는 화장료 조성물을 제공하게 된다.As described above, the present invention not only suppresses the synthesis of melanin by inhibiting the synthesis of signal transduction agents related to melanin synthesis, which is a cause of blemishes, freckles and skin pigmentation, but also exhibits a whitening effect on the cosmetic substrate. The present invention provides a cosmetic composition exhibiting a skin stimulating alleviation effect and an immune enhancing effect such as skin cell death suppressing effect, which reduces skin irritation caused by inflammation, and an enzyme activity inhibitory effect related to inflammation induction.
이상에서는 본 발명의 바람직한 실시예에 대해 설명하였으나 당해 기술분야에서 통상의 지식을 가진 자라면 본원 발명의 요지를 벗어남이 없이 다양한 변형실 시가 가능할 것이며, 이러한 변형실시는 본원발명의 보호범위에 속하는 것으로서 본원발명의 보호범위는 특허청구범위에 기재된 바에 따라 해석되어야 할 것이다.In the above description of the preferred embodiment of the present invention, those skilled in the art will be able to practice various modifications without departing from the gist of the present invention, and such modifications are within the scope of protection of the present invention. The protection scope of the present invention should be construed as described in the claims.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040035047A KR100563547B1 (en) | 2004-05-18 | 2004-05-18 | A cosmetic composition containing extract of Lespedeza bicolor turczaninow var and/or Solanum nigrum L |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040035047A KR100563547B1 (en) | 2004-05-18 | 2004-05-18 | A cosmetic composition containing extract of Lespedeza bicolor turczaninow var and/or Solanum nigrum L |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20050110148A KR20050110148A (en) | 2005-11-23 |
KR100563547B1 true KR100563547B1 (en) | 2006-03-27 |
Family
ID=37285712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040035047A KR100563547B1 (en) | 2004-05-18 | 2004-05-18 | A cosmetic composition containing extract of Lespedeza bicolor turczaninow var and/or Solanum nigrum L |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100563547B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100847478B1 (en) | 2007-04-13 | 2008-07-21 | 에이비씨나노텍 주식회사 | Composition for functional soap comprising gold or silver nanoparticle and extraction polymer of black nightshade as effective ingredients, and production method thereof |
KR101161346B1 (en) | 2010-01-29 | 2012-07-02 | 계명대학교 산학협력단 | The extracting method of compositions having anti-oxidant effect, anti-inflammatory effect and whitening effect from Lespedeza bicolor |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100702891B1 (en) * | 2005-08-17 | 2007-04-03 | 대구한의대학교산학협력단 | Cosmetic composition comprising an extract of Lespedeza bicolor having anti-oxidative activity |
KR101407061B1 (en) * | 2012-10-23 | 2014-06-12 | 주식회사 엑티브온 | Composition for inhibiting activity of tyrosinase |
KR101925358B1 (en) * | 2017-03-27 | 2019-02-27 | (주)자작나눔 | How to make sari wood liquid soap |
KR101976572B1 (en) * | 2018-11-30 | 2019-05-09 | 충청남도 | A natural antiseptic composition comprising extract of Lespedeza cuneata G. Don |
-
2004
- 2004-05-18 KR KR1020040035047A patent/KR100563547B1/en active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100847478B1 (en) | 2007-04-13 | 2008-07-21 | 에이비씨나노텍 주식회사 | Composition for functional soap comprising gold or silver nanoparticle and extraction polymer of black nightshade as effective ingredients, and production method thereof |
KR101161346B1 (en) | 2010-01-29 | 2012-07-02 | 계명대학교 산학협력단 | The extracting method of compositions having anti-oxidant effect, anti-inflammatory effect and whitening effect from Lespedeza bicolor |
Also Published As
Publication number | Publication date |
---|---|
KR20050110148A (en) | 2005-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101832288B1 (en) | Method of preparing green tea extract by using magma seawater, carbonated water, or bedrock water, and functional cosmetic composition comprising the same | |
KR100732564B1 (en) | Cosmetic composition containing extract of fraxinus chinensis | |
KR101026879B1 (en) | Producing method of cosmetic composition for improving skin wrinkle | |
KR101078888B1 (en) | A cosmetic composition comprising tissue cultured Echinaceae adventitious roots and an preparing method thereof | |
KR20170076147A (en) | Composition for improving skin | |
KR100563547B1 (en) | A cosmetic composition containing extract of Lespedeza bicolor turczaninow var and/or Solanum nigrum L | |
KR100860605B1 (en) | Cosmetic composition comprising extract of pinus strobus bark and niacinamide | |
KR101027113B1 (en) | Method for cosmetic composition containing pine endodermis extract from Pinus thunbergii Parl. | |
KR101208013B1 (en) | A skin-care agent containing mycoleptodonoides aitchisonii mycelium extract | |
KR101909578B1 (en) | External composition for skin containing extract of Potentilla stolonifera var. quelpaertensis Nakai | |
KR20090097550A (en) | Cosmetic composition containing schizandrin and extracts | |
KR20100018139A (en) | A skin-care agent containing sedum sarmentosum extracts and lipoic acid-peg conjugated compounds | |
KR100525994B1 (en) | A cosmetic composition containing an extract of herbal medicines | |
KR101939112B1 (en) | Composition of skin external application containing ginsenoside F1 | |
KR101317433B1 (en) | The cosmetic composition for skin whitening comprising the mixture of extract of Hovenia dulcia, Platycodon grandiflorum, wheat bud and sage | |
KR101909533B1 (en) | Composition of skin external application containing ginsenoside F1 | |
KR100552269B1 (en) | A cosmetic composition containing extract of Campsis grandiflora and/or Torreya nucifera seed | |
KR20030086933A (en) | A cosmetic composition containing an Extract of Zostera Marina L. | |
KR20080098925A (en) | Cometic compositions containing extract of paeonia suffruticosa andrew | |
KR100935329B1 (en) | Fruit extract of rubus hirsutus thunb. having skin whitening activity containing ellagic acid | |
KR100983526B1 (en) | A cosmetic composition containing Cupressus funebris extract | |
KR101274606B1 (en) | Cosmetic composition containing the extract of jujube extracted with high pressure | |
KR20110062159A (en) | Cosmetic composition containing panax ginseng callus extracts for skin whitening | |
KR101844980B1 (en) | External composition for skin containing extract of Salix blinii H.Lev. | |
KR100961761B1 (en) | Cosmetic composition containing Japanese Quince Extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130311 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140314 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150316 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160316 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170316 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180306 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20190221 Year of fee payment: 14 |